Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA.
Department of Pediatric Gastroenterology and Nutrition, Emma Children's Hospital/Academic Medical Center, Amsterdam, The Netherlands.
Neurogastroenterol Motil. 2018 Feb;30(2). doi: 10.1111/nmo.13184. Epub 2017 Aug 10.
To evaluate the long-term efficacy of sacral nerve stimulation (SNS) in children with constipation and describe patient benefit and parent satisfaction.
Using a prospective patient registry, we identified patients <21 years old with constipation treated with SNS for >2 years. We compared symptoms, medical treatment, PedsQL Gastrointestinal Symptom Scale (GSS), Fecal Incontinence Quality of Life Scale (FIQL), and Fecal Incontinence Severity Index (FISI) before SNS and at follow-up. We contacted parents to administer the Glasgow Children's Benefit Inventory (GCBI) and a parent satisfaction questionnaire.
We included 25 children (52% male, median age 10 years): 16 had functional constipation, six anorectal malformation, two tethered spinal cord, and one Hirschsprung's disease. Defecation frequency did not change after SNS but patients reporting fecal incontinence decreased from 72% to 20% (P<.01) and urinary incontinence decreased from 56% to 28% (P=.04). Patients using laxatives decreased from 64% to 44% (ns) and patients using antegrade enemas decreased from 48% to 20% (P=.03). GSS, most FIQL domains, and FISI were improved at follow-up. Six (24%) patients had complications requiring further surgery. Of the 16 parents contacted, 15 (94%) parents indicated positive health-related benefit and all would recommend SNS to other families.
CONCLUSIONS & INFERENCES: Sacral nerve stimulation is a promising and durable treatment for children with refractory constipation, and appears particularly effective in decreasing fecal incontinence. Although a quarter of patients experienced complications requiring additional surgery, nearly all parents reported health-related benefit. Future studies to identify predictors of treatment response and complications are needed.
评估骶神经刺激(SNS)治疗儿童便秘的长期疗效,并描述患者获益和家长满意度。
使用前瞻性患者登记处,我们确定了接受 SNS 治疗>2 年的<21 岁便秘患者。我们比较了症状、药物治疗、儿童生活质量量表胃肠道症状评分(PedsQL GSS)、粪便失禁生活质量量表(FIQL)和粪便失禁严重程度指数(FISI)在 SNS 治疗前和随访时的情况。我们联系了家长,让他们填写格拉斯哥儿童受益量表(GCBI)和家长满意度问卷。
我们纳入了 25 名儿童(52%为男性,中位年龄 10 岁):16 名患有功能性便秘,6 名患有肛门直肠畸形,2 名患有脊髓栓系,1 名患有先天性巨结肠。SNS 治疗后排便频率没有变化,但报告粪便失禁的患者从 72%降至 20%(P<.01),尿失禁从 56%降至 28%(P=.04)。使用泻药的患者从 64%降至 44%(无统计学意义),使用逆行灌肠的患者从 48%降至 20%(P=.03)。GSS、大多数 FIQL 领域和 FISI 在随访时得到改善。6 名(24%)患者出现需要进一步手术的并发症。在联系的 16 名家长中,15 名(94%)家长表示有积极的健康相关获益,并且都愿意向其他家庭推荐 SNS。
骶神经刺激是治疗难治性便秘儿童的一种有前途且持久的治疗方法,尤其在减少粪便失禁方面效果显著。尽管四分之一的患者出现需要进一步手术的并发症,但几乎所有家长都报告了健康相关获益。需要进一步研究以确定治疗反应和并发症的预测因素。